GEN Exclusives

More »

GEN News Highlights

More »
Jan 6, 2011

Receptos and Lilly Enter Agreement Focused on a GPCR Target

  • Receptos and Eli Lilly agreed to research and develop orally delivered small molecule modulators of an undisclosed GPCR target. They will advance the candidates into preclinical development based on shared structure-based drug design efforts that employ Receptos’s technology for determining GPCR crystal structure.

    Receptos’ approach to GPCR drug discovery combines traditional screening information with biophysical ligand screening using pure and stable receptor protein, chemistry structure-activity relationships, novel biological insight into allosteric binding sites, site specific mutagenesis to probe residue-ligand interactions, GPCR crystal structure, and co-crystal structure iterations.

    “The lead-generation focus of the collaboration aligns with our company’s strategic plan to contribute to the development of therapeutically relevant candidates for high-value targets, while maintaining freedom to conduct our own drug development, either with partners or on an independent basis,” says Faheem Hasnain, president and CEO of Receptos.


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Should “Special K” Get Special Treatment?

In the near term, what is the best way to use ketamine in treating depression?